| 牛培勤 李静静 徐选福 周莹群 费鸿翔.益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化的临床研究[J].现代生物医学进展英文版,2016,16(17):3291-3294. |
| 益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化的临床研究 |
| The Clinical Effect of YiQiRuanGan Soup Combined with Entecavir inTreatment of Chronic Hepatitis and Liver Fibrosis |
| |
| DOI： |
| 中文关键词: 益气软肝方 恩替卡韦 慢性肝炎肝纤维化 层黏蛋白 透明质酸 |
| 英文关键词: YiQiRuanGan soup Entecavir Chronic hepatitis liver fibrosis Laminin Hyaluronic acid |
| 基金项目: |
|
| Hits: 963 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化的临床效果。方法：选择2012 年9 月至2015 年2 月在我院内
科治疗的慢性肝炎肝纤维化患者98 例，采用随机抽签方法分为治疗组与对照组各49 例，对照组给予恩替卡韦治疗，治疗组给予
益气软肝方联合恩替卡韦治疗，都治疗3 个月。对治疗后两组疗效、肝功能指标及肝纤维化指标进行检测与比较。结果：治疗后治
疗组的总有效率为98.0 %，对照组为85.7 %，治疗组总有效率明显高于对照组(P<0.05)。与治疗前相比，治疗后两组肝功能指标均
有所改善（P<0.05），治疗后两组肝功能指标对比差异不明显（P>0.05）。两组治疗后的血清HA、CⅣ、PCⅢ和LN 值都明显低于治
疗前(P<0.05)，同时与对照组相比，治疗后治疗组的血清HA、CⅣ、PCⅢ和LN 值明显较低(P<0.05)。结论：益气软肝方联合恩替卡
韦治疗慢性肝炎肝纤维化能提高治疗疗效，改善肝功能指标及肝纤维化指标，其作用机制可能与降低肝纤维化因子的释放有关。 |
| 英文摘要: |
| Objective:To investigate the clinical effects of YiQiRuanGan soup combined with entecavir for treatment of chronic
hepatitis liver fibrosis.Methods:From September 2012 to February 2015, selected 98 patients with chronic hepatitis liver fibrosis in our
hospital were equally divided randomly into treatment group and control group. The patients in control group received entecavir treatment,
and the patients in treatment group were given YiQiRuanGan soup combined with entecavir treatment, and all treatment cycles
were three months. Then the efficacy, indexes of liver function and liver fibrosis indexes were examined and compared.Results:After
treatment, the total effective rate in the treatment group and the control group were 98.0 % and 85.7 %respectively, which were significantly
higher in treatment group with statistical significance compared with control group (P<0.05). The index of liver function after
treatment were all improved with significant difference compared with before treatment (P<0.05). But the difference of index of liver
function between two groups after treatment was no statistically significance (P>0.05). After treatment, the serum level of HA, CⅣ, PC
Ⅲ and LN were significantly lower than before treatment (P<0.05), while the serum level of HA, CⅣ, PCⅢ and LN in the treatment
group after treatment were significantly lower than that of the control group (P<0.05).Conclusion:YiQiRuanGan soup combined with
entecavir for treating chronic hepatitis liver fibrosis could improve the therapeutic efficacy, improve the indexes of liver function index
and hepatic fibrosis, and its mechanismmay be associated with reducing the release of liver fibrosis cytokines. |
|
View Full Text
View/Add Comment Download reader |
| Close |
